BMI1 and glioma: Indeed, dual inhibition of EZH2 and BMI1 has already been shown to have more pronounced effects in vitro and in vivo in glioma stem cells than either agent alone (Jin et al., 2017) and in multiple myeloma (Alzrigat et al., 2017).